<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-3-1-1">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>			
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>	
			</div>

			<div class="slide-title red">
				Chemical structure of eltrombopag
			</div>


			<div class="content-container">
				

				<div class="content-left">
					
					<ul>
						<li><span>Eltrombopag is a biphenyl hydrazone<sup>1–4</sup></span>
							<ul>
								<li><span>Empirical formula: C<sub>25</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub></span></li>
								<li><span>Orally bioavailable small molecule (molecular weight: 442 Da)<sup>2</sup></span></li>
							</ul>
						</li>
						<li><span>Chemical structure of eltrombopag<sup>3</sup></span>
							<ul>
								<li><span>Acidic (CO2H) group at one end</span></li>
								<li><span>ALipophilic (CH3) groups at the other end</span></li>
								<li><span>Metal chelate group in the centre<sup>3</sup></span>
									<ul>
										<li><span>Eltrombopag shares similar structural chelator properties to known iron chelators</span></li>
									</ul>
								</li>
							</ul>
						</li>
					</ul>

				</div>

				<div class="content-right">
					
					<div class="red-label">Molecular structure of eltrombopag<sup>1,5</sup></div>

					<img src="media/images/slide_3-1-1/picture1.png" alt="">

					<p class="small-print">Structure consists of a chelator backbone with a lipophilic end and an acidic end</p>

				</div>

				

			</div>

		</div>

		<div class="information-overlay overlay">

			<header>Chemical structure of eltrombopag</header>
				
			<ul>
				<li><span>The generic name of eltrombopag is eltrombopag olamine<sup>6</sup></span></li>
			</ul>

		</div>

		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Erickson-Miller C <i>et al. Exp Hematol</i> 2005;33:85</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/DaviesJK-2007-BrJHaematol-v136p549.pdf"><span>Bussel JB & Pinheiro MP. In <i>Hematopoietic Growth Factors in Oncology</i>. 2011</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/EmedicalBlogspot-2011.pdf"><span>Kuter DJ <i>et al. Semin Hematol</i> 2010;47:243</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/TheGenevaFoundationForMedicalEducationandResearch-2014.pdf"><span>GlaxoSmithKline. Promacta (eltrombopag). Prescribing Information (draft). 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/DokalI-2008-BloodRev-v22p141.pdf"><span>Roth M <i>et al. Blood</i> 2012;120:386 (supplemental material)</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/DokalI-2008-BloodRev-v22p141.pdf"><span>GlaxoSmithKline. Eltrombopag tablets for oral use. Prescribing Information (draft). 2014</span></li>
			</ol>

		</div>

	</div>
</div>